Serina Therapeutics Makes Waves in mRNA Vaccine Development
Serina Therapeutics, Inc. (NYSE American: SER), a pioneering biotechnology firm focused on enriching the drug development landscape, recently announced significant contributions to the mRNA vaccine sector. An upcoming presentation at the 4th LNP Formulation & Process Development Summit in Boston promises to introduce groundbreaking insights.
Key Insights from Randall Moreadith
Randall Moreadith, M.D., Ph.D., serves as the Chief Development Officer at Serina and is set to captivate the audience with a presentation titled "The PEG Dilemma – A Solution." This session aims to tackle persistent challenges encountered with anti-PEG antibodies in mRNA vaccines and therapeutics. These problems have raised concerns across the medical community, and Serina's innovative POZ-lipid technology is poised to offer an immune-silent alternative to traditional PEG-lipids.
New Data on POZ-Lipid Technology
During this pivotal presentation, Dr. Moreadith plans to unveil research demonstrating that Serina's POZ-lipid does not trigger the IgM or IgG antibody response even after repeated doses in a vaccine format. This is a notable contrast to conventional PEG-lipid formulations, which often induce robust antibody responses.
The Significance of Anti-PEG Antibodies
These anti-PEG antibodies are increasingly recognized as contributors to serious adverse events, including anaphylaxis, observed in individuals administered PEGylated mRNA vaccines, such as those developed by prominent pharmaceutical companies. The revelation that Serina’s POZ-lipid does not provoke an immune response could herald a new era of safer and more effective lipid nanoparticle (LNP) formulations, which are critical for the advancement of gene therapy and RNA-based medicinal products.
About Serina Therapeutics
Serina operates at the forefront of clinical-stage biotechnology, actively developing a diverse range of drug candidates aimed at treating neurological conditions and other medical indications. The company’s proprietary POZ Platform offers broad potential for enhancing the efficacy and safety across multiple modalities, including small molecules and antibody-based drug conjugates (ADCs).
Commitment to Innovation and Research
Headquartered in Huntsville, Alabama, Serina Therapeutics thrives on innovation, developing its cutting-edge solutions on the campus of the HudsonAlpha Institute of Biotechnology. This collaboration underscores their commitment to not just address current medical challenges but to also lead in the exploration of novel therapeutic pathways.
Contact and Inquiries
Individuals interested in learning more about Serina's advancements in biotechnology or the upcoming presentation can reach out directly. Their representative, Stefan Riley, is available for inquiries at sriley@serinatherapeutics.com or by calling (256) 327-9630.
Frequently Asked Questions
What is Serina Therapeutics known for?
Serina Therapeutics is a biotechnology company focused on developing advanced drug product candidates aimed at treating various medical conditions, particularly in the neurological domain.
What is the POZ Platform?
The POZ Platform is Serina Therapeutics' proprietary drug optimization technology designed to enhance the safety and efficacy of drug formulations, including lipid nanoparticles for mRNA vaccines.
What challenges does the POZ-lipid technology address?
The POZ-lipid technology aims to mitigate the issues related to anti-PEG antibodies that can cause adverse immune reactions in patients receiving mRNA vaccines.
Where is Serina Therapeutics located?
Serina Therapeutics is located in Huntsville, Alabama, operating on the HudsonAlpha Institute of Biotechnology campus.
How can I contact Serina Therapeutics for more information?
You can contact Serina Therapeutics through their representative Stefan Riley at sriley@serinatherapeutics.com or call (256) 327-9630.
